Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 21, 2026

Germany About to Find Out Whether Its Recovery Is Real

View original at finance.yahoo.com
Germany About to Find Out Whether Its Recovery Is Real Photographer: Ben Kilb/Bloomberg (Bloomberg) -- Data from Germany in the coming days will shed light on whether Europe’s largest economy is on the cusp of a meaningful revival or still being hampered by Donald Trump’s tariffs and its own chronic shortcomings…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Calendar-adjusted annual growth would be 0.8% in 2026, up from 0.3% in 2025

    80% confidence
  • Expecting flat fourth-quarter GDP reading for Canada

    80% confidence
  • Central bank would remain cautious on easing

    80% confidence
  • Musings about pulling US out of USMCA trade deal sound like negotiating tactic

    80% confidence
  • Don't anticipate meaningful near-term economic acceleration in Germany, forecasting growth of 0.2% in Q1 2026 and 0.3% in Q2 2026

    80% confidence
  • Increased public spending on infrastructure and defense expected to provide larger boost in second half of 2026, lifting quarterly GDP growth to 0.4%

    80% confidence
  • Stepped up calls for rate cuts

    80% confidence
  • Cited growth in industry and notable strength in construction for Germany's Q4 2025 GDP advance

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com